Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
JAMA Network Open|April 7, 2025
Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T TherapyJames P Long, Rishab Prakash, Paul Edelkamp, et al.
Leukemia & Lymphoma|January 22, 2021
The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapyAlexander Augustyn, L Jeffrey Medeiros, Ethan B Ludmir, et al.
International Journal of Radiation Oncology, Biology, Physics|September 20, 2024
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell TherapyGohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, et al.
British Journal of Haematology|January 31, 2021
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysisPaolo Strati, Phoebe T M Cheng, Raphael E Steiner, et al.
British Journal of Haematology|September 7, 2022
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplantHua-Jay J Cherng, Guofan Xu, Lei Feng, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Frontiers in Immunology|February 17, 2025
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasGohar S Manzar, Chelsea C Pinnix, Stephanie O Dudzinski, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Cancer|November 20, 2023
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 studyMax J Gordon, Lei Feng, Paolo Strati, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphomaHaopeng Yang, Kotaro Arita, Kevin Bowman, et al.
Pageof 16